Advances in Custom Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advances in Custom Synthesis
As contract manufacturers and drug companies meet at Informex, the stage is set for the latest in pharmaceutical chemical development.


Pharmaceutical Technology
Volume 34, Issue 2, pp. 46-51


Patricia Van Arnum
Seeking ways to improve or achieve the synthesis of an active pharmaceutical ingredient (API) or intermediate used in the synthesis of an API is an ongoing task for contract manufacturers, pharmaceutical companies, research centers, and universities. Some recent advances in asymmetric synthesis, natural product synthesis, and green chemistry are improving select synthethic routes.

Asymmetric synthesis


(PHOTO: MIRIAM MASLO/SPL, SCIENCE PHOTO LIBRARY, GETTY IMAGES)
Synthesizing enantiomerically pure compounds is an important area of process research and development. Researchers at Ohio State University in Columbus, Ohio, reported on the use of parallel kinetic synthesis, whereby a single catalyst transformed a racemic mixture of aziridines to a pair of regioisomeric products with good yield and high enantioselectivity (1). The researchers used a dimeric yttrium salen catalyst to accelerate the ring opening of aliphatic aziridines by trimethylsilylazide, thereby inducing nucleophilic attack at the primary position of one enantiomer and the secondary position of the other (1).

In another development, researchers at Rutgers University in New Brunswick, New Jersey, advanced an approach for enantioselective amine acylation. The researchers reported on the use of a small-molecule catalyst to acylate amines enantioselectively. Specifically, the researchers described that acyl pyridinium salts derived from 4-(dimethylamino)pyridine and benzoic anhydride are made chiral from the interaction with a chiral thiourea anion receptor (2).

Natural products

Natural products provide potential drug candidates, but the synthetic route to a natural product can be difficult to achieve. A recent breakthrough was reported by researchers at the Scripps Research Institute in La Jolla, California, who successfully synthesized palua'amine, a complex alkaloid that has shown potential as a possible anticancer, antibacterial, and antifungal agent. The compound is derived from a sponge off Palau, an island nation in the Pacific Ocean. The compound was discovered in 1993, but the complexity of the molecule has made its synthesis very challenging, according to a Jan. 7, 2010, Scripps Research Institute press release.

The compound has eight contiguous stereogenic centers, several reactive nitrogen-containing moieties, and a highly strained core that forms a junction between two five- membered rings (3). Scripps Research chemist Phil Baran, who led the team that made the breakthrough, has been working on the synthesis since he arrived as a faculty member at Scripps Research more than six years ago, according to the release.


Nanoburrs: a novel nanoparticle in drug delivery
The key breakthrough was a cyclization strategy to make the strained core (3). The synthesis of palau'amine was achieved via highly chemoselective transformations, cascade reactions, and a transannular cyclization to secure the trans-5,5 ring junction (4). One of the more significant later advances was applying silver-mediated oxidation, which stabilized an intermediate to permit the five final steps to a macro-paula'amine, according to the release.

Another group of researchers at Scripps Research Institute reported on a strategy for aryl carbon–hydrogen olefination, an approach that may be useful for synthesizing natural products and other drugs. The palladium-catalyzed Mizoroki–Heck reaction, which couples aryl halides with olefins, is widely used to forge carbon–carbon bonds (5). But this approach has certain disadvantages, namely installing the halide of interest is not always easy, according to a Dec. 3, 2009 Scripps Research Institute release. An alternative method, palladium-catalyzed carbon–hydrogenation olefination, has been limited to specific cases that generally include electron-rich heterocyles and/or stoichiometric palladium (5). The researchers instead used a carboxylate-directed palladium (II)-catalyzed carbon–hydrogen olefination reaction using phenylacetic acid and 3-phenylpropionic acid substrates with oxygen at atmospheric pressure as the oxidant and amino-acid derivatives as the ligands. This approach was used to produce commercial drug scaffolds and to synthesize 2-tetralone and naphtholic acid natural product cores (5).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here